Bio-Path Holdings, Inc. (BPTH) Appoints Amy P. Sing, M.D. To Its Board Of Directors

Bio-Path Holdings, Inc. (BPTH) Appoints Amy P. Sing, M.D. To Its Board Of Directors

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced the appointment of Amy P. Sing, M.D. to its Board of Directors, bringing the number of board members to five.

Dr. Sing, 56, currently serves as Senior Director of Medical Affairs at Genomic Health, Inc., a leading publicly held biotechnology company that assists physicians and patients in making personalized cancer treatment decisions. 

Suggested Articles

The takeover centers on a near-approval anti-CGRP antibody that could address Lundbeck’s need for near-term revenue drivers.

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.